pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
Cemiplimab 350 MG Intravenous Solution
Phase 2 · small molecule · Clear Cell Renal Cell Carcinoma
Cemiplimab 350 MG Intravenous Solution for Clear Cell Renal Cell Carcinoma is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Internal code OU-SCC-LAG-BOOST
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron UK Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Clear Cell Renal Cell Carcinoma
- Status
- active
- Trials
- 1